<DOC>
	<DOCNO>NCT01535924</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose bendamustine hydrochloride give together gemcitabine hydrochloride see well work treat patient relapsed refractory Hodgkin lymphoma . Drugs use chemotherapy , gemcitabine hydrochloride bendamustine hydrochloride , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug , combination chemotherapy , may kill cancer cell .</brief_summary>
	<brief_title>Gemcitabine Bendamustine Patients With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate toxicity determine maximum tolerate dose ( MTD ) combine bendamustine ( bendamustine hydrochloride ) gemcitabine ( gemcitabine hydrochloride ) patient relapse refractory Hodgkin 's lymphoma . II . To determine overall response rate bendamustine gemcitabine patient relapse refractory Hodgkin 's lymphoma . SECONDARY OBJECTIVES : I . To determine whether therapy bendamustine set relapsed refractory Hodgkin 's lymphoma impact future stem cell collection . OUTLINE : This phase I , dose-escalation study bendamustine hydrochloride follow phase II study . Patients receive gemcitabine hydrochloride intravenously ( IV ) 30 minute day 1 bendamustine hydrochloride IV 30 minute day 1 2 . Treatment repeat every 21-28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month 2 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically documented Classical Hodgkin 's lymphoma recurrent refractory standard chemotherapy ; core biopsy acceptable contain adequate tissue primary diagnosis immunophenotyping ; bone marrow biopsy sole mean diagnosis acceptable Patients Hodgkin 's lymphoma may one follow World Health Organization subtypes : Nodular sclerosis Hodgkin 's lymphoma Lymphocyterich Hodgkin 's lymphoma Mixed cellularity Hodgkin 's lymphoma Lymphocyte depletion Hodgkin 's lymphoma Nodular lymphocyte predominant Hodgkin 's lymphoma Patients must relapse progress least one prior therapy Patients relapse refractory disease follow stem cell transplantation permit No prior treatment bendamustine ; prior therapy gemcitabine permit Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Measurable disease must present either physical examination image study ; nonmeasurable disease alone acceptable Measurable disease : lesion accurately measure least two dimension &gt; = 1.0 x 1.0 cm computerize tomography ( CT ) , PET/CT ( positron emission tomography/CT ) , magnetic resonance imaging ( MRI ) Nonmeasurable disease : lesion , include small lesion ( less 1.0 x 1.0 cm ) truly nonmeasurable lesion ; lesion consider nonmeasurable include follow : Bone lesion ( lesion present note ) Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Bone marrow ( involvement Hodgkin 's lymphoma note ) Nonpregnant nonnursing ; due teratogenic potential agent , pregnant nursing patient may enrol ; woman men reproductive potential agree use effective mean birth control Patients human immunodeficiency virus ( HIV ) infection eligible ; patient HIV infection must meet following : No evidence coinfection hepatitis B C ; cluster differentiation ( CD ) 4+ count &gt; = 400/mm ; evidence resistant strain HIV ; antiHIV therapy HIV viral load &lt; 50 copy HIV ribonucleic acid ( RNA ) /mL ; history acquire immune deficiency syndrome ( AIDS ) define condition Granulocytes &gt; = 1000/μl Platelet count &gt; = 75,000/μl Creatinine = &lt; 20 mg/dL Bilirubin = &lt; 2.0 mg/dL Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 2.0 x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>